46. Malignant rheumatoid arthritis
4,183 clinical trials,   2,538 drugs   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02936180
(ClinicalTrials.gov)
October 20167/10/2016Standard Versus High Dose Inactivated Influenza Vaccine in RAImproving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population?Rheumatoid ArthritisBiological: HD-TIV;Biological: SD-QIVMcGill University Health Centre/Research Institute of the McGill University Health CentreThe Arthritis Society, CanadaUnknown status18 YearsN/AAll280Phase 4Canada
2NCT02748785
(ClinicalTrials.gov)
September 20158/9/2015MTX Discontinuation and Vaccine ResponseEffect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical TrialArthritis, RheumatoidDrug: Methotrexate;Biological: Seasonal Influenza vaccineSeoul National University HospitalNULLCompleted18 YearsN/ABoth277Phase 4Korea, Republic of
3NCT02311855
(ClinicalTrials.gov)
August 20144/12/2014Duration of Immune Response to Influenza Vaccination in Patients With RADuration of Immune Response to Influenza Vaccination in Patients With Rheumatoid Arthritis Receiving Treatment With Biologic AgentsRheumatoid ArthritisBiological: Influenza vaccineBassett HealthcareNew York State Department of HealthCompleted40 Years75 YearsAll87Phase 4United States
4NCT01980836
(ClinicalTrials.gov)
November 20134/11/2013Effect of Tocilizumab to the Cellular Immune Response to Influenza VaccineThe Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid ArthritisRheumatoid Arthritis;Cellular Immune ResponseBiological: Seasonal influenza vaccineTel-Aviv Sourasky Medical CenterNULLNot yet recruiting18 YearsN/ABoth40Phase 4Israel
5NCT01436370
(ClinicalTrials.gov)
October 201115/9/2011TIV and High Dose TIV in Subjects With Rheumatoid ArthritisA Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage LevelsInfluenzaBiological: Trivalent inactivated influenza vaccineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years64 YearsAll102Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01151644
(ClinicalTrials.gov)
April 201025/6/2010Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesSafety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesRheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DMBiological: Anti-pandemic H1N1 influenza vaccineUniversity of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloActive, not recruitingN/AN/ABoth5000Phase 4Brazil
7NCT00993668
(ClinicalTrials.gov)
September 20099/10/2009Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal VaccinesA Phase 4, Randomized, Single-blind, Placebo-controlled, Multicenter Study to Evaluate the Immunogenicity of Pneumococcal and Influenza Vaccines in Adult Subjects With Rheumatoid Arthritis Receiving Certolizumab Pegol or PlaceboRheumatoid ArthritisOther: Placebo;Biological: Certolizumab pegolUCB PharmaNULLCompleted18 YearsN/AAll224Phase 4United States
8NCT00466037
(ClinicalTrials.gov)
September 200524/4/2007The Effect of Rituximab on the Humoral Response to Influenza VaccineVaccination Against Influenza in Rheumatoid Arthritis Patients: The Effect of Rituximab on the Humoral ResponseRheumatoid ArthritisBiological: Influenza vaccineTel-Aviv Sourasky Medical CenterNULLTerminated18 Years85 YearsBoth64N/ANULL